TY - JOUR
T1 - Frontiers proposal. National Institute on Aging "bench to bedside
T2 - Estrogen as a case study"
AU - Asthana, Sanjay
AU - Brinton, Roberta Diaz
AU - Henderson, Victor W.
AU - McEwen, Bruce S.
AU - Morrison, John H.
AU - Schmidt, Peter J.
N1 - Funding Information:
The following is a Frontiers Proposal for the development of research initiatives to investigate effects of ovarian steroid hormones on cognitive aging and brain function. This proposal for the NIA of the US National Institutes of Health has four goals:
Funding Information:
On 28–29 September 2004, the National Institute on Aging (NIA) of the United States (US) National Institutes of Health convened scientists from basic science, epidemiology, and clinical trials fields for a workshop held in Bethesda, MD. Cosponsors for the workshop, entitled “Bench to Bedside: Estrogen as a Case Study” were the National Institute of Mental Health, Office of Research on Women’s Health, and the Alzheimer’s Association. The focus of the workshop was on scientific data concerning the use of estrogens and progestogens in the aging female brain: what is already known and what will be required to translate discoveries from the laboratory workbench, from epidemiology, and from clinical trials into everyday medical practice.
PY - 2009/9
Y1 - 2009/9
N2 - On 28-29 September 2004, the National Institute on Aging (NIA) convened scientists for a workshop on the aging female brain focused on translating into clinical practice discoveries concerning estrogens and progestogens. Workshop objectives were to examine effects of estrogen and progestogen on brain and cognitive function in relation to aging, to examine consistencies and apparent discrepancies between Women's Health Initiative Memory Study findings and other research on cognitive function, to determine whether additional hormone interventions could be developed in this area, and to offer advice on design of clinical trials for other interventions that might ameliorate cognitive aging. Following the workshop, participants joined by other interested scientists organized into regional work groups to continue the dialogue begun in Bethesda and to propose recommendations for NIA. The resulting recommendations, referred to as the "Frontiers Proposal for Estrogen and Cognitive Aging", acknowledge the persistence of critical gaps in our understanding of how decline in ovarian steroid secretion during reproductive aging and use of ovarian steroid hormone therapy affect normal brain function and risk for late-life neurodegenerative disorders such as Alzheimer's disease. There is a pressing need for preclinical, human, and integrated studies on the relationship between the menopausal transition and midlife exposures to estrogens, progestogens and related compounds, and risks for age-associated cognitive disorders. Research is also needed on better predictors of adverse cognitive outcomes, valid biomarkers for risks associated with hormone therapy use, enhanced tools for monitoring brain function and disease progression, and novel forms of therapy for improving long-term cognitive outcomes.
AB - On 28-29 September 2004, the National Institute on Aging (NIA) convened scientists for a workshop on the aging female brain focused on translating into clinical practice discoveries concerning estrogens and progestogens. Workshop objectives were to examine effects of estrogen and progestogen on brain and cognitive function in relation to aging, to examine consistencies and apparent discrepancies between Women's Health Initiative Memory Study findings and other research on cognitive function, to determine whether additional hormone interventions could be developed in this area, and to offer advice on design of clinical trials for other interventions that might ameliorate cognitive aging. Following the workshop, participants joined by other interested scientists organized into regional work groups to continue the dialogue begun in Bethesda and to propose recommendations for NIA. The resulting recommendations, referred to as the "Frontiers Proposal for Estrogen and Cognitive Aging", acknowledge the persistence of critical gaps in our understanding of how decline in ovarian steroid secretion during reproductive aging and use of ovarian steroid hormone therapy affect normal brain function and risk for late-life neurodegenerative disorders such as Alzheimer's disease. There is a pressing need for preclinical, human, and integrated studies on the relationship between the menopausal transition and midlife exposures to estrogens, progestogens and related compounds, and risks for age-associated cognitive disorders. Research is also needed on better predictors of adverse cognitive outcomes, valid biomarkers for risks associated with hormone therapy use, enhanced tools for monitoring brain function and disease progression, and novel forms of therapy for improving long-term cognitive outcomes.
KW - Aging
KW - Alzheimer's disease
KW - Cognition
KW - Dementia
KW - Estrogen
KW - Menopause
KW - Progestogen
UR - http://www.scopus.com/inward/record.url?scp=69549133273&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=69549133273&partnerID=8YFLogxK
U2 - 10.1007/s11357-009-9087-2
DO - 10.1007/s11357-009-9087-2
M3 - Article
AN - SCOPUS:69549133273
SN - 0161-9152
VL - 31
SP - 199
EP - 210
JO - Age
JF - Age
IS - 3
ER -